articleThe Lancet OncologyNov 27, 2009Closed access

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

University Hospital Carl Gustav Carus · Vienna General Hospital · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

960
total citations
FWCI
35.02
Percentile
100%
References
38
Citations per year

Authors

18

Topics & keywords

Keywords
  • Medicine
  • Folinic acid
  • Clinical endpoint
  • FOLFIRI
  • Oxaliplatin
  • Cetuximab
  • Irinotecan
  • Response Evaluation Criteria in Solid Tumors
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding